New drug combo aims to tame rare artery disease
NCT ID NCT07451665
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two new drugs, vunakizumab and ivarmacitinib, for people with active Takayasu arteritis (TAK), a rare disease that causes inflammation in large blood vessels. The trial will enroll 180 adults aged 18-70 whose disease is still active despite standard treatments. Researchers will compare the drugs' ability to control the disease over 52 weeks, aiming to reduce reliance on steroids.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TAKAYASU ARTERITIS (TAK) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Anzhen Hospital Capital Medical University
Beijing, Beijing Municipality, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, China
-
Jiaozuo People's Hospital
Jiaozuo, Henan, China
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
-
People's Hospital of Guangxi Zhuang Autonomous Region
Nanning, Guangxi, China
-
People's Hospital of Ningxia Hui Autonomous Region
Yinchuan, Ningxia, China
-
People's Hospital of Xinjiang Uygur Autonomous Region
Ürümqi, Xinjiang, China
-
Shenzhen People's Hospital
Shenzhen, Guangdong, China
-
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
-
The Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Neimenggu, China
-
The First Affiliated Hospital of Baotou Medical College
Baotou, Neimenggu, China
-
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
-
The First Affiliated Hospital of Sun Yat-sen University
Guanzhou, Guangdong, China
-
The First Hospital of China Medical University
Shenyang, Liaoning, China
-
The First Hospital of Jilin University
Ch’ang-ch’un, Jilin, China
-
The First Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
-
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
-
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
-
Union Hospital Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China
-
Xuanwu Hospital Capital Medical University
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.